Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $14,564.52 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Sanjay Nayak sold 1,759 shares of Ocular Therapeutix stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $8.28, for a total transaction of $14,564.52. Following the completion of the transaction, the insider directly owned 330,653 shares in the company, valued at $2,737,806.84. The trade was a 0.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Sanjay Nayak also recently made the following trade(s):

• On Thursday, February 12th, Sanjay Nayak sold 10,348 shares of Ocular Therapeutix stock. The stock was sold at an average price of $9.04, for a total transaction of $93,545.92.

Ocular Therapeutix Stock Performance

Ocular Therapeutix stock traded up $0.55 during mid-day trading on Wednesday, reaching $9.50. 7,845,017 shares of the company were exchanged, compared to its average volume of 7,060,435. The firm’s 50-day simple moving average is $10.53 and its two-hundred day simple moving average is $11.62. Ocular Therapeutix, Inc. has a twelve month low of $5.78 and a twelve month high of $16.44. The firm has a market cap of $2.07 billion, a PE ratio of -6.60 and a beta of 0.90. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.32 and a current ratio of 15.39.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. The company had revenue of $13.25 million during the quarter, compared to the consensus estimate of $16.13 million. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. Ocular Therapeutix’s quarterly revenue was down 22.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.29) EPS. Equities analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

More Ocular Therapeutix News

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Director Richard L. Lindstrom bought 60,229 shares at an average $7.66 (a ~32% increase in his stake) — a sizable insider purchase that signals confidence and provides direct demand support for the shares. Read More.
• Positive Sentiment: Ocular will present detailed SOL‑1 data at the 49th Macula Society meeting and host an investor webcast — a potential catalyst if data or management commentary clarifies commercial or clinical outlooks. Read More.
• Neutral Sentiment: The company will participate in March investor conferences, increasing visibility with institutional investors but not introducing new clinical data by itself. Read More.
• Neutral Sentiment: Several small institutional moves were reported (new / larger stakes by boutique managers). These are modest in dollar terms and mainly signal ongoing institutional interest rather than a major position shift. (No single large fund reported a material cut.)
• Negative Sentiment: Short interest jumped ~27.8% in February to ~14.7M shares (about 6.9% of shares outstanding) with a ~3.0 days‑to‑cover — higher shorting can amplify downside on negative news and adds volatility risk.
• Negative Sentiment: Multiple insiders sold shares in late Feb (including Pravin Dugel, Sanjay Nayak, Jeffrey Heier, Peter Kaiser and Nadia Waheed). While some sales are modest relative to holdings, the cluster of transactions can be perceived as a negative signal. Representative SEC disclosure: Read More.
• Negative Sentiment: Needham lowered its price target to $18 (from $20) — a downward adjustment from a sell‑side firm that could temper sentiment among growth/biotech investors. Read More.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on OCUL shares. Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Thursday, January 22nd. Jefferies Financial Group reissued a “buy” rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Needham & Company LLC dropped their target price on shares of Ocular Therapeutix from $20.00 to $18.00 and set a “buy” rating for the company in a report on Friday, February 20th. TD Cowen restated a “buy” rating on shares of Ocular Therapeutix in a research report on Thursday, October 30th. Finally, Citigroup reiterated an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Ocular Therapeutix currently has an average rating of “Moderate Buy” and a consensus target price of $23.78.

Institutional Investors Weigh In On Ocular Therapeutix

A number of hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Ocular Therapeutix by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 93,619 shares of the biopharmaceutical company’s stock worth $686,000 after purchasing an additional 5,156 shares during the period. Caxton Associates LLP purchased a new stake in Ocular Therapeutix during the first quarter worth approximately $248,000. Allianz Asset Management GmbH increased its position in shares of Ocular Therapeutix by 63.2% in the second quarter. Allianz Asset Management GmbH now owns 61,200 shares of the biopharmaceutical company’s stock worth $568,000 after acquiring an additional 23,700 shares in the last quarter. AlphaQuest LLC increased its position in shares of Ocular Therapeutix by 200.8% in the second quarter. AlphaQuest LLC now owns 20,196 shares of the biopharmaceutical company’s stock worth $187,000 after acquiring an additional 13,483 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its stake in shares of Ocular Therapeutix by 62.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,392 shares during the period. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.